Results 91 to 100 of about 40,707 (134)

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. [PDF]

Clin Cancer Res
Guercio BJ, Pietzak EJ, Ravichandran V, Chen JF, Shah RH, Peters V, Regazzi AM, Niglio SA, Aggen DH, Funt SA, Donahue TF, Goh AC, Cha EK, Wong P, Richards AL, Cobbs CC, Donat SM, Dalbagni G, Bochner BH, Iyer G, Donoghue MTA, Ostrovnaya I, Al-Ahmadie HA, Rosenberg JE, Teo MY.   +24 more
europepmc   +1 more source

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer. [PDF]

J Cardiovasc Pharmacol
Quagliariello V, Passariello M, Belardo M, Esposito A, Paone M, Berretta M, Iovine M, Barbato M, Canale ML, Paccone A, Inno A, Oliva S, Maurea C, Forte P, Mauriello A, Fonderico C, Gallucci G, Tarantini L, Camilli M, Camerini A, De Lorenzo C, Maurea N.   +21 more
europepmc   +1 more source

Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Scoping Review. [PDF]

Pharmaceuticals (Basel)
Tacchi C, Convertino I, Bocci G.
europepmc   +1 more source

Role of CTLA-4 blockade and dacarbazine therapy following anti-PD-1 resistance in melanoma. [PDF]

Discov Oncol
Urbonas V, Dulskas A.
europepmc   +1 more source

Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies. [PDF]

Curr Oncol Rep
Allen-Tejerina AM, Giannakis P, Ho Lai Yau T, Hillyar CRT, Rallis KS.   +4 more
europepmc   +1 more source

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. [PDF]

Nat Commun
Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, Goekkurt E, Dechow TN, Ettrich TJ, Hofheinz RD, Luley KB, Pink D, Lindig U, Folprecht G, Schuch G, Bitzer M, Heinemann V, Angermeier S, Bolling C, Loose M, Junge S, Pauligk C, Al-Batran SE.   +20 more
europepmc   +1 more source